FDA Brief

Warning letters Drugs

FDA warning letter to

Shirish M. Gadgeel, M.D.

High riskIssued Sep 4, 2025Posted Sep 9, 2025Center for Drug Evaluation and Research (CDER)

Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.

What happened

FDA inspected Dr. Gadgeel's clinical site from August 5 to August 23, 2024, reviewing his conduct of three investigational drug studies. FDA found a subject was enrolled and given study drug without meeting a required inclusion criterion, another subject stayed on study drug after confirmed disease progression, and blood samples for optional genetic analysis were collected at two visits without the separate signed consent. FDA reviewed his September 13, 2024 response and said it lacked enough detail on how he would oversee study procedures.

What FDA found

  1. A subject was enrolled and treated through at least Cycle 6 even though a required eligibility document was missing and the record showed something else.

    21 CFR 312.60
  2. A subject with confirmed disease progression stayed on the investigational drug until January 3, 2022, including doses given before the sponsor approved continued dosing.

    21 CFR 312.60
  3. Blood samples for optional genetic analysis were drawn at two visits before the subject signed the separate genetic consent form.

    21 CFR 312.60 and 21 CFR 50.20
  4. His written corrective action plan did not explain in enough detail how he would oversee study procedures such as eligibility and consent.

What FDA wants

Within 15 business days of receiving the letter, Dr. Gadgeel must write to FDA describing the actions he has taken to prevent similar violations. FDA says failure to address the matter adequately may lead to regulatory action.

Who should pay attention

  • clinical investigators and site research staff running oncology trials
  • sponsors and contract research organizations relying on site protocol and consent compliance
  • IRBs and research compliance offices overseeing trial sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk